Inhibition of mTOR can downregulate the senescence-associated secretory phenotype (SASP), thereby reducing systemic inflammation.

“so it's interesting it's similar to what near was saying for metformin is there's a regulation of the sasp so these inflammatory cytokines that are secreted by senescent cells that accumulate as we age that is regulated in part by mtor so inhibiting mtor will decrease sas which will decrease systemic inflammation”